ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.290
-0.010 (-0.43%)
Dec 5, 2025, 4:00 PM EST - Market closed
ImmunityBio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ImmunityBio stock have an average target of 9.83, with a low estimate of 5.00 and a high estimate of 24. The average target predicts an increase of 329.26% from the current stock price of 2.29.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +948.03% | Nov 13, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +948.03% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +249.34% | Sep 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +948.03% | Sep 8, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +948.03% | Aug 26, 2025 |
Financial Forecast
Revenue This Year
113.12M
from 14.75M
Increased by 667.18%
Revenue Next Year
213.03M
from 113.12M
Increased by 88.32%
EPS This Year
-0.46
from -0.62
EPS Next Year
-0.34
from -0.46
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 121.3M | 258.0M | ||||
| Avg | 113.1M | 213.0M | ||||
| Low | 106.6M | 152.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 722.5% | 128.1% | ||||
| Avg | 667.2% | 88.3% | ||||
| Low | 622.6% | 35.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.37 | -0.25 | ||||
| Avg | -0.46 | -0.34 | ||||
| Low | -0.63 | -0.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.